Pharsight

1. List of Abilify drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8017615	OTSUKA	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Jun, 2024 (1 year, 4 months from now)
US7115587	OTSUKA	Aripiprazole complex formulation and method	Jul, 2024 (1 year, 5 months from now)
US7550445	OTSUKA	Aripiprazole complex formulation and method	Jul, 2024 (1 year, 5 months from now)
US8017615 (Pediatric)	OTSUKA	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Dec, 2024 (1 year, 10 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 07 June, 2006

Treatment: Treatment of schizophrenia

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Submission Date	ANDA(s) Filed	Last patent expiry	180 day status
1 mg/mL	20 Dec, 2007	1	24 Apr, 2022	Extinguished
2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg	15 Nov, 2006	8	20 Oct, 2014	Extinguished
10 mg, 15 mg, 20 mg and 30 mg	15 Nov, 2006	1	20 Oct, 2014	Extinguished

Strength	Dosage	Availability
10MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
15MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
20MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
30MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

2. List of Abilify Maintena Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8030313	OTSUKA PHARM CO LTD	Controlled release sterile injectable aripiprazole formulation and method	Oct, 2024 (1 year, 8 months from now)
US8722679	OTSUKA PHARM CO LTD	Controlled release sterile injectable aripiprazole formulation and method	Oct, 2024 (1 year, 8 months from now)
US7807680	OTSUKA PHARM CO LTD	Controlled release sterile injectable aripiprazole formulation and method	Oct, 2024 (1 year, 8 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
300 mg/vial and 400 mg/vial	20 Dec, 2021	1		24 Sep, 2033

Strength	Dosage	Availability
300MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
300MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

3. List of Abilify Mycite Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8017615	OTSUKA	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof	Jun, 2024 (1 year, 4 months from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

4. List of Abraxane drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7923536 (Pediatric)	ABRAXIS BIOSCIENCE	Compositions and methods of delivery of pharmacological agents	Jun, 2024 (1 year, 4 months from now)
US8314156 (Pediatric)	ABRAXIS BIOSCIENCE	Compositions and methods of delivery of pharmacological agents	Jun, 2024 (1 year, 4 months from now)
US8138229 (Pediatric)	ABRAXIS BIOSCIENCE	Compositions and methods of delivery of pharmacological agents	Jun, 2024 (1 year, 4 months from now)
US7820788	ABRAXIS BIOSCIENCE	Compositions and methods of delivery of pharmacological agents	Oct, 2024 (1 year, 8 months from now)

Exclusivity	Exclusivity Expiration
M	Dec 6, 2022
Pediatric Exclusivity (PED)	Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of lung cancer; Treatment of breast cancer; Treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg/vial	11 Dec, 2015	1		27 Oct, 2024

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription

5. List of Acular Ls drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377982	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US8207215	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US8906950	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US8946281	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US8648107	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US9216167	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US8541463	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	May, 2024 (1 year, 3 months from now)
US8377982 (Pediatric)	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	Nov, 2024 (1 year, 9 months from now)
US8207215 (Pediatric)	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	Nov, 2024 (1 year, 9 months from now)
US8541463 (Pediatric)	ALLERGAN	Ketorolac tromethamine compositions for treating or preventing ocular pain	Nov, 2024 (1 year, 9 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of controlling postoperative ocular pain and burning/stinging in a patient; A method of treating or preventing ocular pain and burning; A method of treating ocular pain; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or reducing ocular pain and burning/stinging

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.004	28 Jan, 2005	1	05 Nov, 2009	05 May, 2011	Extinguished

Strength	Dosage	Availability
0.4%	SOLUTION/DROPS;OPHTHALMIC	Prescription

6. List of Acuvail drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952	ALLERGAN	Compositions for delivery of therapeutics into the eyes and methods for making and using same	Aug, 2024 (1 year, 6 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0045	24 Aug, 2011	1	10 Feb, 2014	15 Aug, 2029	Eligible

Strength	Dosage	Availability
0.45%	SOLUTION/DROPS;OPHTHALMIC	Prescription

7. List of Adasuve drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9370629	ALEXZA PHARMS	Self-contained heating unit and drug-supply unit employing same	May, 2024 (1 year, 3 months from now)
US8991387	ALEXZA PHARMS	Self-contained heating unit and drug-supply unit employing same	May, 2024 (1 year, 3 months from now)
US7458374	ALEXZA PHARMS	Method and apparatus for vaporizing a compound	Aug, 2024 (1 year, 6 months from now)
US7537009	ALEXZA PHARMS	Method of forming an aerosol for inhalation delivery	Oct, 2024 (1 year, 8 months from now)

Drugs and Companies using LOXAPINE ingredient

Market Authorisation Date: 21 December, 2012

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
10MG	POWDER;INHALATION	Prescription

8. List of Airduo Digihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987229	TEVA PHARM	Process for preparing a medicament	Sep, 2024 (1 year, 6 months from now)
US9616024	TEVA PHARM	Process for preparing a medicament	Sep, 2024 (1 year, 6 months from now)

Exclusivity	Exclusivity Expiration
M	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

9. List of Aldara drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7696159	BAUSCH	Treatment for basal cell carcinoma	Apr, 2024 (1 year, 1 month from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696159 (Pediatric)	BAUSCH	Treatment for basal cell carcinoma	Oct, 2024 (1 year, 7 months from now)

Drugs and Companies using IMIQUIMOD ingredient

Market Authorisation Date: 27 February, 1997

Treatment: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); Works through the induction of interferon and other cytokines

Dosage: CREAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.05	17 Oct, 2006	1	25 Feb, 2010	24 Aug, 2010	Eligible

Strength	Dosage	Availability
5%	CREAM;TOPICAL	Prescription

10. List of Aliqopa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7511041	BAYER HEALTHCARE	Fused azole-pyrimidine derivatives	May, 2024 (1 year, 3 months from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 14, 2022
Orphan Drug Exclusivity (ODE)	Sep 14, 2024

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

NCE-1 date: September, 2021

Market Authorisation Date: 14 September, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
60MG/VIAL	POWDER;INTRAVENOUS	Prescription

11. List of Aloxi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947724	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US9066980	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US8729094	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US9457020	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US8518981	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US9439854	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US7947725	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US8598218	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US9457021	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US9125905	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US7960424	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US9173942	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US8598219	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jan, 2024 (11 months from now)
US8598218 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)
US9066980 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)
US9457021 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)
US9125905 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)
US8598219 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)
US8729094 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)
US9457020 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)
US9439854 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)
US9173942 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)
US7947725 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)
US7947724 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)
US8518981 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)
US7960424 (Pediatric)	HELSINN HLTHCARE	Liquid pharmaceutical formulations of palonosetron	Jul, 2024 (1 year, 5 months from now)

Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2003

Treatment: Prevention of chemotherapy-induced nausea and vomiting

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.05 mg/mL, 1.5 mL and 5 mL vials	27 May, 2011	3	13 Oct, 2015	13 Apr, 2015	Extinguished

Strength	Dosage	Availability
EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	INJECTABLE;INTRAVENOUS	Discontinued
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	INJECTABLE;INTRAVENOUS	Discontinued

12. List of Alphagan P drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8858961 (Pediatric)	ALLERGAN	Compositions containing alpha-2-adrenergic agonist components	Mar, 2024 (1 year, 30 days from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 19 August, 2005

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.001	20 Dec, 2006	1		28 Jul, 2021	Extinguished
0.0015	03 Nov, 2006	1		28 Jan, 2022	Extinguished

Strength	Dosage	Availability
0.1%	SOLUTION/DROPS;OPHTHALMIC	Prescription

13. List of Altabax drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207191	ALMIRALL	Process, salts, composition and use	Aug, 2024 (1 year, 6 months from now)

Drugs and Companies using RETAPAMULIN ingredient

Market Authorisation Date: 12 April, 2007

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: OINTMENT;TOPICAL

Strength	Dosage	Availability
1%	OINTMENT;TOPICAL	Prescription

14. List of Amitiza drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7795312	SUCAMPO PHARMA LLC	Method for treating abdominal discomfort	Sep, 2024 (1 year, 7 months from now)

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 31 January, 2006

Treatment: Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
8 mcg and 24 mcg	20 Aug, 2012	1	27 Jun, 2022	30 Aug, 2022	Extinguished

Strength	Dosage	Availability
8MCG	CAPSULE;ORAL	Prescription
24MCG	CAPSULE;ORAL	Prescription

15. List of Anjeso drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10471067	BAUDAX	Nanoparticulate meloxicam formulations	Feb, 2024 (1 year, 23 days from now)
US10463673	BAUDAX	Nanoparticulate meloxicam formulations	Feb, 2024 (1 year, 23 days from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
30MG/ML (30MG/ML)	SOLUTION;INTRAVENOUS	Prescription

16. List of Arikayce Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9827317	INSMED INC	Sustained release of antiinfectives	Apr, 2024 (1 year, 2 months from now)
US8802137	INSMED INC	Sustained release of antiinfectives	Apr, 2024 (1 year, 2 months from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN)	Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

Strength	Dosage	Availability
EQ 590MG BASE/8.4ML	SUSPENSION, LIPOSOMAL;INHALATION	Prescription

17. List of Armonair Digihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024	TEVA PHARM	Process for preparing a medicament	Sep, 2024 (1 year, 6 months from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Jul 9, 2024
New Strength (NS)	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH	POWDER;INHALATION	Discontinued
0.113MG/INH	POWDER;INHALATION	Discontinued
0.232MG/INH	POWDER;INHALATION	Discontinued
0.03MG/INH	POWDER;INHALATION	Discontinued

18. List of Atripla drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8592397	GILEAD SCIENCES	Compositions and methods for combination antiviral therapy	Jan, 2024 (11 months from now)
US8716264	GILEAD SCIENCES	Compositions and methods for combination antiviral therapy	Jan, 2024 (11 months from now)
US9744181	GILEAD SCIENCES	Compositions and methods for combination antiviral therapy	Jan, 2024 (11 months from now)
US9457036	GILEAD SCIENCES	Compositions and methods for combination antiviral therapy	Jan, 2024 (11 months from now)

Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 12 July, 2006

Treatment: Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv-1 infection in adults; Treatment of hiv infection

Dosage: TABLET;ORAL

19. List of Auryxia drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7767851	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 17 days from now)
US8338642	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 17 days from now)
US9757416	KERYX BIOPHARMS	Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 17 days from now)
US9328133	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 17 days from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050316	KERYX BIOPHARMS	Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 17 days from now)
US8754257	KERYX BIOPHARMS	Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 17 days from now)
US8609896	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 17 days from now)
US8299298	KERYX BIOPHARMS	Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same	Feb, 2024 (1 year, 17 days from now)
US8754258	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 17 days from now)
US8901349	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 17 days from now)
US8846976	KERYX BIOPHARMS	Ferric organic compounds, uses thereof and methods of making same	Feb, 2024 (1 year, 17 days from now)

Drugs and Companies using FERRIC CITRATE ingredient

Market Authorisation Date: 05 September, 2014

Treatment: Control of serum phosphorous levels

Dosage: TABLET;ORAL

20. List of Auvi-q drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10314977	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US9737669	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8920377	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8361029	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US9056170	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8313466	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8608698	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US7918823	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US10737028	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8425462	KALEO INC	Devices, systems, and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US9833573	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 10 August, 2012

Treatment: Method to treat severe allergic emergencies in patients weighing 7.5 to 15 kg (16.5 to 33 lbs)

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

21. List of Bosulif drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42376	PF PRISM CV	Substituted 3-cyanoquinolines	Apr, 2024 (1 year, 2 months from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 19, 2024

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Market Authorisation Date: 04 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

22. List of Brilinta drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46276	ASTRAZENECA	Triazolo(4,5-D)pyrimidine compounds	Oct, 2024 (1 year, 8 months from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Nov 5, 2023
M	May 9, 2025
Pediatric Exclusivity (PED)	Nov 28, 2023

Drugs and Companies using TICAGRELOR ingredient

Market Authorisation Date: 20 July, 2011

Treatment: Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction; Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction; Treatment of stroke in patients with acute coronary syndrome or a history of myocardial infarction; Treatment of myocardial infarction in patients with acute coronary syndrome or a history of myocardial infarction; Reduction of the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack; Treatment of myocardial infarction or stroke in patients with coronary artery disease at high risk for such events; Reduction of the rate of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events

Dosage: TABLET;ORAL

23. List of Bydureon drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7563871	ASTRAZENECA AB	Polymer-based sustained release device	Apr, 2024 (1 year, 2 months from now)
US9238076	ASTRAZENECA AB	Polymer-based sustained release device	Apr, 2024 (1 year, 2 months from now)
US9238076 (Pediatric)	ASTRAZENECA AB	Polymer-based sustained release device	Oct, 2024 (1 year, 8 months from now)
US7563871 (Pediatric)	ASTRAZENECA AB	Polymer-based sustained release device	Oct, 2024 (1 year, 8 months from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Jul 22, 2024
M	Feb 15, 2022
Pediatric Exclusivity (PED)	Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

24. List of Bydureon Bcise drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076	ASTRAZENECA AB	Polymer-based sustained release device	Apr, 2024 (1 year, 2 months from now)
US7563871	ASTRAZENECA AB	Polymer-based sustained release device	Apr, 2024 (1 year, 2 months from now)
US7563871 (Pediatric)	ASTRAZENECA AB	Polymer-based sustained release device	Oct, 2024 (1 year, 8 months from now)
US9238076 (Pediatric)	ASTRAZENECA AB	Polymer-based sustained release device	Oct, 2024 (1 year, 8 months from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Jul 22, 2024
M	Feb 15, 2022
Pediatric Exclusivity (PED)	Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

25. List of Cabometyx drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284	EXELIXIS INC	C-met modulators and method of use	Sep, 2024 (1 year, 7 months from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Sep 17, 2028
New Indication (I)	Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma

Dosage: TABLET;ORAL

26. List of Children's Advil drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640	GLAXOSMITHKLINE	Pharmaceutical suspension composition	May, 2024 (1 year, 3 months from now)

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 27 June, 1996

Treatment: NA

Dosage: SUSPENSION;ORAL

27. List of Children's Advil Allergy Sinus drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640	GLAXOSMITHKLINE	Pharmaceutical suspension composition	May, 2024 (1 year, 3 months from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 February, 2004

Treatment: NA

Dosage: SUSPENSION;ORAL

28. List of Chloraprep One-step drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6991394	BECTON DICKINSON CO	Liquid applicator with a mechanism for fracturing multiple ampoules	Jan, 2024 (11 months from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient

Market Authorisation Date: 14 July, 2000

Treatment: NA

Dosage: SPONGE;TOPICAL

29. List of Chlorhexidine Gluconate drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7066916	SAGE PRODS	Disinfectant delivery system, and method of providing alcohol-free disinfection	Feb, 2024 (1 year, 16 days from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Market Authorisation Date: 25 April, 2005

Treatment: Disinfection of patient skin prior to an invasive procedure

Dosage: CLOTH;TOPICAL

30. List of Combivent Respimat drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474	BOEHRINGER INGELHEIM	Piston-pumping system having o-ring seal properties	Aug, 2024 (1 year, 6 months from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

31. List of Complera drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8716264	GILEAD SCIENCES INC	Compositions and methods for combination antiviral therapy	Jan, 2024 (11 months from now)
US9457036	GILEAD SCIENCES INC	Compositions and methods for combination antiviral therapy	Jan, 2024 (11 months from now)
US8592397	GILEAD SCIENCES INC	Compositions and methods for combination antiviral therapy	Jan, 2024 (11 months from now)
US9744181	GILEAD SCIENCES INC	Compositions and methods for combination antiviral therapy	Jan, 2024 (11 months from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 10 August, 2011

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

32. List of Contrave drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278544	NALPROPION	Compositions for affecting weight loss	Apr, 2024 (1 year, 2 months from now)
US7462626	NALPROPION	Compositions for affecting weight loss	Jul, 2024 (1 year, 5 months from now)
US8815889	NALPROPION	Compositions and methods for increasing insulin sensitivity	Jul, 2024 (1 year, 5 months from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance

Dosage: TABLET, EXTENDED RELEASE;ORAL

33. List of Daliresp drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618142	ASTRAZENECA	Process for the preparation of roflumilast	Mar, 2024 (1 year, 1 month from now)
US8536206	ASTRAZENECA	Process for the preparation of roflumilast	Mar, 2024 (1 year, 1 month from now)
US8604064	ASTRAZENECA	Process for the preparation of roflumilast	Mar, 2024 (1 year, 1 month from now)

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 28 February, 2011

Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations

Dosage: TABLET;ORAL

34. List of Dexilant drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722084 (Pediatric)	TAKEDA PHARMS USA	Controlled release preparation	Apr, 2024 (1 year, 2 months from now)
US8784885 (Pediatric)	TAKEDA PHARMS USA	Controlled release preparation	Apr, 2024 (1 year, 2 months from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

35. List of Dexilant Solutab drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784885 (Pediatric)	TAKEDA PHARMS USA	Controlled release preparation	Apr, 2024 (1 year, 2 months from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

36. List of Dextenza drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254267	OCULAR THERAPEUTIX	Composite hydrogel drug delivery systems	Sep, 2024 (1 year, 7 months from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Oct 7, 2024

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: NA

Dosage: INSERT;OPHTHALMIC

37. List of Differin drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7737181	GALDERMA LABS LP	Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders	Aug, 2024 (1 year, 6 months from now)

Drugs and Companies using ADAPALENE ingredient

Market Authorisation Date: 19 June, 2007

Treatment: NA

Dosage: GEL;TOPICAL

38. List of Dificid drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586551 (Pediatric)	CUBIST PHARMS LLC	18-membered macrocycles and analogs thereof	Jan, 2024 (11 months from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Jan 24, 2023
Orphan Drug Exclusivity (ODE)	Jan 24, 2027
Pediatric Exclusivity (PED)	Jul 24, 2023

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 27 May, 2011

Treatment: NA

Dosage: TABLET;ORAL

39. List of Diprivan drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476010	FRESENIUS KABI USA	Propofol formulations with non-reactive container closures	Dec, 2024 (1 year, 9 months from now)

Drugs and Companies using PROPOFOL ingredient

Market Authorisation Date: 02 October, 1989

Treatment: NA

Dosage: INJECTABLE;INJECTION

40. List of Duavee drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6479535	WYETH PHARMS	2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations	May, 2024 (1 year, 3 months from now)

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

Market Authorisation Date: 03 October, 2013

Treatment: Prevention of postmenopausal osteoporosis; Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

41. List of Durysta drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707	ALLERGAN INC	Hypotensive lipid-containing biodegradable intraocular implants and related implants	Apr, 2024 (1 year, 2 months from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

42. List of Dutrebis drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169780 (Pediatric)	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Apr, 2024 (1 year, 2 months from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 06 February, 2015

Treatment: NA

Dosage: TABLET;ORAL

43. List of Dymista drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8163723 (Pediatric)	MYLAN SPECIALITY LP	Combination of azelastine and steroids	Feb, 2024 (1 year, 28 days from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 01 May, 2012

Treatment: NA

Dosage: SPRAY, METERED;NASAL

44. List of Entresto drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7468390 (Pediatric)	NOVARTIS PHARMS CORP	Methods of treatment and pharmaceutical composition	May, 2024 (1 year, 3 months from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Oct 1, 2022
M	Feb 16, 2024
Pediatric Exclusivity (PED)	Apr 1, 2023

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

45. List of Envarsus Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077096	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US8889186	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US8623411	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US8889185	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US8586084	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US8486993	VELOXIS PHARMS INC	Solid dispersions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US9161907	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US10548880	VELOXIS PHARMS INC	Solid dispersions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US9757362	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US8617599	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US8623410	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US9763920	VELOXIS PHARMS INC	Solid dispersions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US8591946	VELOXIS PHARMS INC	Modified release compositions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)
US7994214	VELOXIS PHARMS INC	Solid dispersions comprising tacrolimus	Aug, 2024 (1 year, 6 months from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jul 10, 2022

Drugs and Companies using TACROLIMUS ingredient

Market Authorisation Date: 10 July, 2015

Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient

Dosage: TABLET, EXTENDED RELEASE;ORAL

46. List of Epiduo drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7964202	GALDERMA LABS LP	Method for treatment of common acne	Sep, 2024 (1 year, 6 months from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Market Authorisation Date: 08 December, 2008

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

47. List of Equetro drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6977253	VALIDUS PHARMS	Methods for the treatment of bipolar disorder using carbamazepine	May, 2024 (1 year, 3 months from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 10 December, 2004

Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

48. List of Evekeo Odt drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130580	ARBOR PHARMS LLC	Taste-masked pharmaceutical compositions	Apr, 2024 (1 year, 2 months from now)

Drugs and Companies using AMPHETAMINE SULFATE ingredient

Market Authorisation Date: 30 January, 2019

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

49. List of Evoclin drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7374747	MYLAN	Pharmaceutical foam	Jan, 2024 (11 months from now)
US7141237	MYLAN	Pharmaceutical foam	Feb, 2024 (1 year, 2 days from now)

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 22 October, 2004

Treatment: Treatment of acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

50. List of Evzio drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10737028	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US9737669	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US9056170	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8361029	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8608698	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8313466	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US7918823	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8425462	KALEO INC	Devices, systems, and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US10314977	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

51. List of Evzio (autoinjector) drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8608698	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8425462	KALEO INC	Devices, systems, and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US9737669	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US10314977	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US10737028	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US7918823	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8361029	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US9056170	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8313466	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

52. List of Exservan drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167	MITSUBISHI HOLDINGS	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions	Feb, 2024 (1 year, 19 days from now)
US8603514	MITSUBISHI HOLDINGS	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions	Apr, 2024 (1 year, 2 months from now)

Drugs and Companies using RILUZOLE ingredient

Market Authorisation Date: 22 November, 2019

Treatment: NA

Dosage: FILM;ORAL

53. List of Farxiga drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076	ASTRAZENECA AB	Polymer-based sustained release device	Apr, 2024 (1 year, 2 months from now)

Exclusivity	Exclusivity Expiration
M	Feb 22, 2022
New Indication (I)	Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide

Dosage: TABLET;ORAL

54. List of Fenoglide drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481078	SALIX	Solid dosage form comprising a fibrate	Oct, 2024 (1 year, 7 months from now)
US8124125	SALIX	Solid dosage form comprising a fibrate	Oct, 2024 (1 year, 7 months from now)
US9173847	SALIX	Tablet comprising a fibrate	Oct, 2024 (1 year, 7 months from now)
US7658944	SALIX	Solid dosage form comprising a fibrate	Dec, 2024 (1 year, 10 months from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 10 August, 2007

Treatment: Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides; For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia

Dosage: TABLET;ORAL

55. List of Fentora drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119158	CEPHALON	Effervescent oral fentanyl dosage form and methods of administering fentanyl	Dec, 2024 (1 year, 10 months from now)
US8092832	CEPHALON	Generally linear effervescent oral fentanyl dosage form and methods of administering	Dec, 2024 (1 year, 10 months from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 25 September, 2006

Treatment: NA

Dosage: TABLET;BUCCAL, SUBLINGUAL

56. List of Finacea drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8435498	LEO PHARMA AS	Penetrating pharmaceutical foam	Mar, 2024 (1 year, 29 days from now)

Drugs and Companies using AZELAIC ACID ingredient

Market Authorisation Date: 29 July, 2015

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

57. List of Flonase Sensimist Allergy Relief drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9320862	GLAXOSMITHKLINE CONS	Fluid dispensing device	Nov, 2024 (1 year, 9 months from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 02 August, 2016

Treatment: NA

Dosage: SPRAY, METERED;NASAL

58. List of Fosrenol drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7465465	TAKEDA PHARMS USA	Pharmaceutical formulation comprising lanthanum compounds	Aug, 2024 (1 year, 6 months from now)
US7381428	TAKEDA PHARMS USA	Stabilized lanthanum carbonate compositions	Aug, 2024 (1 year, 6 months from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Market Authorisation Date: 26 October, 2004

Treatment: Reduction of serum phosphate in patients with end stage renal disease

Dosage: TABLET, CHEWABLE;ORAL

59. List of Givlaari drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9708610	ALNYLAM PHARMS INC	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	Jan, 2024 (10 months from now)
US10273477	ALNYLAM PHARMS INC	Therapeutic compositions	Mar, 2024 (1 year, 1 month from now)
US9708615	ALNYLAM PHARMS INC	Therapeutic compositions	Mar, 2024 (1 year, 1 month from now)
US11530408	ALNYLAM PHARMS INC	Therapeutic compositions	May, 2024 (1 year, 3 months from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 20, 2024
Orphan Drug Exclusivity (ODE)	Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

60. List of Gralise drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7438927	ALMATICA	Methods of treatment using a gastric retained gabapentin dosage	Feb, 2024 (1 year, 25 days from now)

Drugs and Companies using GABAPENTIN ingredient

Market Authorisation Date: 28 January, 2011

Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia

Dosage: TABLET;ORAL

61. List of Halaven drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6214865 (Pediatric)	EISAI INC	Macrocyclic analogs and methods of their use and preparation	Jan, 2024 (11 months from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jan 28, 2023
M	Sep 13, 2025
Pediatric Exclusivity (PED)	Mar 13, 2026

Drugs and Companies using ERIBULIN MESYLATE ingredient

Market Authorisation Date: 15 November, 2010

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

62. List of Hycamtin drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8158645	NOVARTIS	Compound, corresponding compositions, preparation and/or treatment methods	Dec, 2024 (1 year, 10 months from now)

Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 11 October, 2007

Treatment: NA

Dosage: CAPSULE;ORAL

63. List of Ilevro drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947295	NOVARTIS	Ophthalmic compositions containing a synergistic combination of two polymers	Jun, 2024 (1 year, 4 months from now)

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

64. List of Inbrija drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7182961	ACORDA	Particulate compositions for pulmonary delivery	Feb, 2024 (1 year, 21 days from now)

Drugs and Companies using LEVODOPA ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER;INHALATION

65. List of Injectafer drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7612109	AM REGENT	Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes	Feb, 2024 (1 year, 4 days from now)

Exclusivity	Exclusivity Expiration
New Strength (NS)	Apr 28, 2024
New Patient Population (NPP)	Nov 19, 2024

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

66. List of Invokamet drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2024 (1 year, 5 months from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2014

Treatment: NA

Dosage: TABLET;ORAL

67. List of Invokamet Xr drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403	JANSSEN PHARMS	Glucopyranoside compound	Jul, 2024 (1 year, 5 months from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

68. List of Ionsys drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6975902	THE MEDICINES CO	Reservoir and a series of related reservoirs for use in an electrotransport drug delivery device and devices comprised thereof	Apr, 2024 (1 year, 1 month from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: NA

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

69. List of Isentress drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169780 (Pediatric)	MERCK SHARP DOHME	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	Apr, 2024 (1 year, 2 months from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 12 October, 2007

Treatment: NA

Dosage: TABLET;ORAL

70. List of Ixempra Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7312237	R-PHARM US LLC	Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases	Aug, 2024 (1 year, 6 months from now)

Drugs and Companies using IXABEPILONE ingredient

Market Authorisation Date: 16 October, 2007

Treatment: Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer

Dosage: INJECTABLE;INTRAVENOUS

71. List of Koselugo drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7425637	ASTRAZENECA	N3 alkylated benzimidazole derivatives as MEK inhibitors	Apr, 2024 (1 year, 2 months from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 10, 2025
Orphan Drug Exclusivity (ODE)	Apr 10, 2027

Drugs and Companies using SELUMETINIB SULFATE ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 10 April, 2020

Treatment: NA

Dosage: CAPSULE;ORAL

72. List of Kuvan drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43797	BIOMARIN PHARM	Methods of administering tetrahydrobiopterin	Nov, 2024 (1 year, 9 months from now)
US7612073	BIOMARIN PHARM	Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring	Nov, 2024 (1 year, 9 months from now)
US9433624	BIOMARIN PHARM	Methods and compositions for the treatment of metabolic disorders	Nov, 2024 (1 year, 9 months from now)
US7566714	BIOMARIN PHARM	Methods and compositions for the treatment of metabolic disorders	Nov, 2024 (1 year, 9 months from now)
US8067416	BIOMARIN PHARM	Methods and compositions for the treatment of metabolic disorders	Nov, 2024 (1 year, 9 months from now)
US8318745	BIOMARIN PHARM	Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride	Nov, 2024 (1 year, 9 months from now)
US7727987	BIOMARIN PHARM	Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride	Nov, 2024 (1 year, 9 months from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2007

Treatment: Kuvan is indicated to reduce blood phenylalanine levels in patients with hyperphenylalaninemia; To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption; Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; For reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia

Dosage: TABLET;ORAL

73. List of Kynmobi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167	SUNOVION PHARMS INC	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions	Feb, 2024 (1 year, 19 days from now)
US8603514	SUNOVION PHARMS INC	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions	Apr, 2024 (1 year, 2 months from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	May 21, 2023

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 May, 2020

Treatment: NA

Dosage: FILM;SUBLINGUAL

74. List of Latisse drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101161	ALLERGAN	Method of enhancing hair growth	May, 2024 (1 year, 3 months from now)

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 24 December, 2008

Treatment: Method of stimulating hair growth; Method of increasing hair growth

Dosage: SOLUTION/DROPS;TOPICAL

75. List of Latuda drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174975	SUNOVION PHARMS INC	Remedy for integration dysfunction syndrome	Feb, 2024 (1 year, 19 days from now)
US9815827	SUNOVION PHARMS INC	Agent for treatment of schizophrenia	Feb, 2024 (1 year, 19 days from now)
US9174975 (Pediatric)	SUNOVION PHARMS INC	Remedy for integration dysfunction syndrome	Aug, 2024 (1 year, 6 months from now)

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2010

Treatment: Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of major depressive episodes associated with bipolar i disorder; Treatment of schizophrenia

Dosage: TABLET;ORAL

76. List of Lazanda drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9078814	BTCP PHARMA	Intranasal spray device containing pharmaceutical composition	Jan, 2024 (11 months from now)
US9814705	BTCP PHARMA	Intranasal spray device containing pharmaceutical composition	Jan, 2024 (11 months from now)
US8889176	BTCP PHARMA	Method of managing or treating pain	Jan, 2024 (11 months from now)
US8216604	BTCP PHARMA	Method of managing or treating pain	Oct, 2024 (1 year, 8 months from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 30 June, 2011

Treatment: Management of breakthrough pain in patients with cancer

Dosage: SPRAY, METERED;NASAL

77. List of Leqvio drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9708610	NOVARTIS	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation	Jan, 2024 (10 months from now)
US9708615	NOVARTIS	Therapeutic compositions	Mar, 2024 (1 year, 1 month from now)
US10273477	NOVARTIS	Therapeutic compositions	Mar, 2024 (1 year, 1 month from now)
US10669544	NOVARTIS	Therapeutic compositions	Mar, 2024 (1 year, 1 month from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

78. List of Linzess drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7745409	ALLERGAN	Methods and compositions for the treatment of gastrointestinal disorders	Jan, 2024 (11 months from now)
US8080526	ALLERGAN	Methods and compositions for the treatment of gastrointestinal disorders	Jan, 2024 (11 months from now)
US7704947	ALLERGAN	Methods and compositions for the treatment of gastrointestinal disorders	Jan, 2024 (11 months from now)
US7371727	ALLERGAN	Methods and compositions for the treatment of gastrointestinal disorders	Jan, 2024 (11 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110553	ALLERGAN	Methods and compositions for the treatment of gastrointestinal disorders	Jan, 2024 (11 months from now)

Drugs and Companies using LINACLOTIDE ingredient

Market Authorisation Date: 30 August, 2012

Treatment: Method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.

Dosage: CAPSULE;ORAL

79. List of Livalo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557993	KOWA CO	Crystalline forms of pitavastatin calcium	Feb, 2024 (1 year, 1 day from now)
US7022713	KOWA CO	Hyperlipemia therapeutic agent	Feb, 2024 (1 year, 18 days from now)
US8557993 (Pediatric)	KOWA CO	Crystalline forms of pitavastatin calcium	Aug, 2024 (1 year, 6 months from now)
US7022713 (Pediatric)	KOWA CO	Hyperlipemia therapeutic agent	Aug, 2024 (1 year, 6 months from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	May 16, 2022
Pediatric Exclusivity (PED)	Nov 16, 2022

Drugs and Companies using PITAVASTATIN CALCIUM ingredient

Market Authorisation Date: 03 August, 2009

Treatment: Adjuncitve therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia

Dosage: TABLET;ORAL

80. List of Lonhala Magnair Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7458372	SUNOVION RESP	Inhalation therapy device	Nov, 2024 (1 year, 9 months from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;INHALATION

81. List of Lynparza drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7981889	ASTRAZENECA	Phthalazinone derivatives	Oct, 2024 (1 year, 8 months from now)
US7449464	ASTRAZENECA	Phthalazinone derivatives	Oct, 2024 (1 year, 8 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8912187	ASTRAZENECA	Phthalazinone derivatives	Mar, 2024 (1 year, 1 month from now)
US9169235	ASTRAZENECA	Phthalazinone derivatives	Mar, 2024 (1 year, 1 month from now)
US9566276	ASTRAZENECA	Phthalazinone derivatives	Mar, 2024 (1 year, 1 month from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	May 8, 2027
New Indication (I)	Mar 11, 2025

Drugs and Companies using OLAPARIB ingredient

Market Authorisation Date: 17 August, 2017

Treatment: Treatment of brca mutated ovarian cancer using parp inhibitor; Treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen

Dosage: TABLET;ORAL

82. List of Mavenclad drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7888328	EMD SERONO INC	Oral formulations of cladribine	Apr, 2024 (1 year, 2 months from now)
US8785415	EMD SERONO INC	Oral formulations of cladribine	Apr, 2024 (1 year, 2 months from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Mar 29, 2022

Drugs and Companies using CLADRIBINE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusion complex, cladribine/cyclodextrin 1:10-1:16 w/w; Treatment of ms with an admixture of (a) an amorphous inclusion complex of cladribine (2cda) and cyclodextrin and (b) amorphous free 2cda and cyclodextrin as a non-inclusion complex, formulated as a solid oral form, w/o sign. amounts of cryst. 2cda

Dosage: TABLET;ORAL

83. List of Megace Es drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7101576	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (1 year, 2 months from now)
US9101540	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (1 year, 2 months from now)
US9107827	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (1 year, 2 months from now)
US9040088	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (1 year, 2 months from now)
US9101549	ENDO PHARMS INC	Nanoparticulate megestrol formulations	Apr, 2024 (1 year, 2 months from now)

Drugs and Companies using MEGESTROL ACETATE ingredient

Market Authorisation Date: 05 July, 2005

Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)

Dosage: SUSPENSION;ORAL

84. List of Methylin drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7691880	SPECGX LLC	Methylphenidate solution and associated methods of administration and production	Oct, 2024 (1 year, 8 months from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2002

Treatment: NA

Dosage: SOLUTION;ORAL

85. List of Mirvaso drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859551	GALDERMA LABS LP	Compounds, formulations, and methods for treating or preventing inflammatory skin disorders	May, 2024 (1 year, 3 months from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 23 August, 2013

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

86. List of Movantik drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7056500	REDHILL	Polymer conjugates of opioid antagonists	Jun, 2024 (1 year, 4 months from now)
US8067431	REDHILL	Chemically modified small molecules	Dec, 2024 (1 year, 10 months from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Market Authorisation Date: 16 September, 2014

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

87. List of Moviprep drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169381	SALIX PHARMS	Colon cleansing compositions and methods	Sep, 2024 (1 year, 6 months from now)
US7658914	SALIX PHARMS	Colon cleansing compositions	Sep, 2024 (1 year, 6 months from now)

Drugs and Companies using ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE ingredient

Market Authorisation Date: 02 August, 2006

Treatment: NA

Dosage: FOR SOLUTION;ORAL

88. List of Mulpleta drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7601746	SHIONOGI INC	Compounds exhibiting thrombopoietin receptor agonism	Sep, 2024 (1 year, 7 months from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 31, 2023

Drugs and Companies using LUSUTROMBOPAG ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 31 July, 2018

Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure

Dosage: TABLET;ORAL

89. List of Myfembree drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058280	MYOVANT SCIENCES	Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof	Jan, 2024 (11 months from now)
US7300935	MYOVANT SCIENCES	Thienopyrimidine compounds and use thereof	Jan, 2024 (11 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9346822	MYOVANT SCIENCES	Thienopyrimidine compounds and use thereof	Feb, 2024 (1 year, 16 days from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 18, 2025
New Product (NP)	May 26, 2024
New Indication (I)	Aug 5, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

90. List of Myrbetriq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7982049 (Pediatric)	APGDI	α-form or β-form crystal of acetanilide derivative	May, 2024 (1 year, 3 months from now)
US7342117 (Pediatric)	APGDI	α-form or β-form crystal of acetanilide derivative	May, 2024 (1 year, 3 months from now)
USRE44872 (Pediatric)	APGDI	Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient	May, 2024 (1 year, 3 months from now)
US8835474 (Pediatric)	APGDI	Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient	May, 2024 (1 year, 3 months from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Mar 25, 2024
Pediatric Exclusivity (PED)	Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 28 June, 2012

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

91. List of Myrbetriq Granules drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7342117 (Pediatric)	APGDI	α-form or β-form crystal of acetanilide derivative	May, 2024 (1 year, 3 months from now)
US7982049 (Pediatric)	APGDI	α-form or β-form crystal of acetanilide derivative	May, 2024 (1 year, 3 months from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Mar 25, 2024
Pediatric Exclusivity (PED)	Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 25 March, 2021

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

92. List of Naloxone Hydrochloride (autoinjector) drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10737028	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8313466	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US7918823	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8361029	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US9737669	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US9056170	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US10314977	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8608698	KALEO INC	Devices, systems and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)
US8425462	KALEO INC	Devices, systems, and methods for medicament delivery	Nov, 2024 (1 year, 9 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 February, 2022

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

93. List of Naropin drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8162915	FRESENIUS KABI USA	Connector for packings containing medical liquids, and corresponding packing for medical liquids	May, 2024 (1 year, 3 months from now)

Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 September, 1996

Treatment: NA

Dosage: SOLUTION;INJECTION

94. List of Nascobal drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940714	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Feb, 2024 (1 year, 25 days from now)
US7404489	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Mar, 2024 (1 year, 1 month from now)
US9415007	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Jul, 2024 (1 year, 5 months from now)
US8003353	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Aug, 2024 (1 year, 5 months from now)
US7879349	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Aug, 2024 (1 year, 5 months from now)
US7229636	ENDO PHARMS INC	Cyanocobalamin low viscosity aqueous formulations for intranasal delivery	Aug, 2024 (1 year, 5 months from now)

Drugs and Companies using CYANOCOBALAMIN ingredient

Market Authorisation Date: 31 January, 2005

Treatment: Cyanocobalamin administration through nasal infusion; Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin

Dosage: SPRAY, METERED;NASAL

95. List of Natesto drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784882	ACERUS	Controlled release delivery system for nasal applications and method of treatment	Feb, 2024 (1 year, 3 days from now)
US8877230	ACERUS	Controlled release delivery system for nasal applications	Feb, 2024 (1 year, 3 days from now)
US8574622	ACERUS	Controlled release delivery system for nasal applications	Feb, 2024 (1 year, 3 days from now)
US8784869	ACERUS	Controlled release delivery system for nasal applications and methods of treatment	Feb, 2024 (1 year, 3 days from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 28 May, 2014

Treatment: A method of testosterone replacement therapy comprising the step of nasally administering to a patient in need of such treatment an effective amount of testosterone gel formulation.; Nasal administration of a testosterone gel to a patient to treat the patient for a condition associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;NASAL

96. List of Ninlaro drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546608	TAKEDA PHARMS USA	Proteasome inhibitors and methods of using the same	Aug, 2024 (1 year, 6 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233115	TAKEDA PHARMS USA	Proteasome inhibitors and methods of using the same	Aug, 2024 (1 year, 6 months from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 20, 2022

Drugs and Companies using IXAZOMIB CITRATE ingredient

Market Authorisation Date: 20 November, 2015

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

97. List of Nocdurna drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560429	FERRING PHARMS INC	Orodispersible dosage forms of desmopressin acetate	Feb, 2024 (1 year, 1 day from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 21 June, 2018

Treatment: Treatment of nocturia due to nocturnal polyuria in adults

Dosage: TABLET;SUBLINGUAL

98. List of Noctiva drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7799761	SERENITY PHARMS LLC	Pharmaceutical compositions including low dosages of desmopressin	Sep, 2024 (1 year, 7 months from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 03 March, 2017

Treatment: NA

Dosage: SPRAY, METERED;NASAL

99. List of Nourianz drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7541363	KYOWA KIRIN	Microcrystal	Nov, 2024 (1 year, 9 months from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 27, 2024

Drugs and Companies using ISTRADEFYLLINE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 27 August, 2019

Treatment: NA

Dosage: TABLET;ORAL

100. List of Nucynta Er drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114383	COLLEGIUM PHARM INC	Abuse-proofed dosage form	Oct, 2024 (1 year, 8 months from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 25 August, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

101. List of Nuplazid drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566271	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Jan, 2024 (11 months from now)
US10028944	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Jan, 2024 (11 months from now)
US8618130	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Jan, 2024 (11 months from now)
US8921393	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Jan, 2024 (11 months from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Market Authorisation Date: 29 April, 2016

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of psychosis or a symptom thereof; Treatment of a neurodegenerative disease or a symptom thereof

Dosage: TABLET;ORAL

102. List of Nuvigil drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346 (Pediatric)	CEPHALON	Pharmaceutical formulations of modafinil	May, 2024 (1 year, 3 months from now)
US7132570 (Pediatric)	CEPHALON	Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil	Jun, 2024 (1 year, 4 months from now)

Drugs and Companies using ARMODAFINIL ingredient

Market Authorisation Date: 15 June, 2007

Treatment: NA

Dosage: TABLET;ORAL

103. List of Nymalize drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8517997	AZURITY	Dispenser for medicaments and method and apparatus for making same	May, 2024 (1 year, 3 months from now)

Drugs and Companies using NIMODIPINE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: NA

Dosage: SOLUTION;ORAL

104. List of Ofev drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7119093	BOEHRINGER INGELHEIM	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition	Feb, 2024 (1 year, 20 days from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Mar 9, 2023
Orphan Drug Exclusivity (ODE)	Sep 6, 2026

Drugs and Companies using NINTEDANIB ESYLATE ingredient

Market Authorisation Date: 15 October, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

105. List of Omegaven drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350186	FRESENIUS KABI USA	Treatment and prevention of liver disease associated with parenteral nutrition (PN)	Nov, 2024 (1 year, 9 months from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 27, 2023
Orphan Drug Exclusivity (ODE)	Jul 27, 2025

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 27 July, 2018

Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12

Dosage: EMULSION;INTRAVENOUS

106. List of Omidria drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173707 (Pediatric)	RAYNER SURGICAL	Ophthalmologic irrigation solutions and method	Jan, 2024 (11 months from now)
US8586633 (Pediatric)	RAYNER SURGICAL	Ophthalmologic irrigation solutions and method	Jan, 2024 (11 months from now)
US9278101 (Pediatric)	RAYNER SURGICAL	Ophthalmologic irrigation solutions and method	Jan, 2024 (11 months from now)
US9399040 (Pediatric)	RAYNER SURGICAL	Ophthalmologic irrigation solutions and method	Jan, 2024 (11 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 May, 2014

Treatment: NA

Dosage: SOLUTION;IRRIGATION

107. List of Omontys drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7528104	TAKEDA PHARMS USA	Peptides that bind to the erythropoietin receptor	May, 2024 (1 year, 3 months from now)
US7414105	TAKEDA PHARMS USA	Peptides that bind to the erythropoietin receptor	May, 2024 (1 year, 3 months from now)
US7084245	TAKEDA PHARMS USA	Peptides that bind to the erythropoietin receptor	May, 2024 (1 year, 3 months from now)
US7919118	TAKEDA PHARMS USA	Spacer moiety for poly (ethylene glycol) modified peptide based compounds	May, 2024 (1 year, 3 months from now)

Drugs and Companies using PEGINESATIDE ACETATE ingredient

Market Authorisation Date: 27 March, 2012

Treatment: Treatment of anemia due to chronic kidney disease

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

108. List of Onzetra Xsail drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119932	CURRAX	Nasal delivery device	Apr, 2024 (1 year, 2 months from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: NA

Dosage: POWDER;NASAL

109. List of Opana Er drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114383	ENDO PHARMS	Abuse-proofed dosage form	Aug, 2024 (1 year, 6 months from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

110. List of Oracea drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8709478	GALDERMA LABS LP	Once daily formulations of tetracyclines	Apr, 2024 (1 year, 2 months from now)
US8394406	GALDERMA LABS LP	Once daily formulations of tetracyclines	Apr, 2024 (1 year, 2 months from now)
US8470364	GALDERMA LABS LP	Once daily formulations of tetracyclines	Apr, 2024 (1 year, 2 months from now)
US8394405	GALDERMA LABS LP	Once daily formulations of tetracyclines	Apr, 2024 (1 year, 2 months from now)

Drugs and Companies using DOXYCYCLINE ingredient

Market Authorisation Date: 26 May, 2006

Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea

Dosage: CAPSULE;ORAL

111. List of Orenitram drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9050311	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	May, 2024 (1 year, 3 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278901	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	May, 2024 (1 year, 3 months from now)
US8252839	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	May, 2024 (1 year, 3 months from now)
US9422223	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	May, 2024 (1 year, 3 months from now)
US7544713	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	Jul, 2024 (1 year, 5 months from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Oct 18, 2022
Orphan Drug Exclusivity (ODE)	Oct 18, 2026

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Market Authorisation Date: 20 December, 2013

Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).

Dosage: TABLET, EXTENDED RELEASE;ORAL

112. List of Orgovyx drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058280	MYOVANT SCIENCES	Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof	Jan, 2024 (11 months from now)
US7300935	MYOVANT SCIENCES	Thienopyrimidine compounds and use thereof	Jan, 2024 (11 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735401	MYOVANT SCIENCES	Thienopyrimidine compounds and use thereof	Feb, 2024 (1 year, 3 days from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent

Dosage: TABLET;ORAL

113. List of Oriahnn (copackaged) drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods related thereto	Jul, 2024 (1 year, 5 months from now)
US7056927	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	Sep, 2024 (1 year, 7 months from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 23, 2023
New Product (NP)	May 29, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 29 May, 2020

Treatment: NA

Dosage: CAPSULE;ORAL

114. List of Orilissa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods related thereto	Jul, 2024 (1 year, 5 months from now)
US7056927	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	Sep, 2024 (1 year, 7 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176211	ABBVIE INC	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto	Jul, 2024 (1 year, 5 months from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis

Dosage: TABLET;ORAL

115. List of Osphena drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8772353	DUCHESNAY	Method for enhancing the bioavalability of ospemifene	Feb, 2024 (1 year, 12 days from now)
US8470890	DUCHESNAY	Method for enhancing the bioavailability of ospemifene	Feb, 2024 (1 year, 12 days from now)
US9855224	DUCHESNAY	Method for enhancing the bioavailability of ospemifene	Feb, 2024 (1 year, 12 days from now)
US9241915	DUCHESNAY	Method for enhancing the bioavailability of ospemifene	Feb, 2024 (1 year, 12 days from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Jan 25, 2022

Drugs and Companies using OSPEMIFENE ingredient

Market Authorisation Date: 26 February, 2013

Treatment: Treatment of dyspareunia associated with menopause; Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; Treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene

Dosage: TABLET;ORAL

116. List of Oxaydo drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492443	ZYLA	Abuse deterrent compositions and methods of making same	May, 2024 (1 year, 3 months from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2011

Treatment: NA

Dosage: TABLET;ORAL

117. List of Ozempic drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7762994	NOVO	Needle mounting system and a method for mounting a needle assembly	May, 2024 (1 year, 3 months from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Jan 16, 2023
New Chemical Entity Exclusivity (NCE)	Dec 5, 2022
New Dosing Schedule (D)	Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

118. List of Ponvory drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43728	JANSSEN PHARMS	Thiazolidin-4-one derivatives	Nov, 2024 (1 year, 9 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018	JANSSEN PHARMS	Thiazolidin-4-one-derivatives	Nov, 2024 (1 year, 9 months from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

Dosage: TABLET;ORAL

119. List of Prevymis drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46791	MERCK SHARP DOHME	Substituted dihydroquinazolines	May, 2024 (1 year, 3 months from now)
US8513255	MERCK SHARP DOHME	Substituted dihydroquinazolines	May, 2024 (1 year, 3 months from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 8, 2024
New Chemical Entity Exclusivity (NCE)	Nov 8, 2022

Drugs and Companies using LETERMOVIR ingredient

NCE-1 date: November, 2021

Market Authorisation Date: 08 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

120. List of Prezcobix drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987	JANSSEN PRODS	Pseudopolymorphic forms of a HIV protease inhibitor	Feb, 2024 (1 year, 15 days from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987 (Pediatric)	JANSSEN PRODS	Pseudopolymorphic forms of a HIV protease inhibitor	Aug, 2024 (1 year, 6 months from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Market Authorisation Date: 29 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.1MG/DELIVERY	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription
EQ 0.15MG/DELIVERY	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription
EQ 0.3MG/DELIVERY	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg and 500 mg	06 Sep, 2016	2		23 Nov, 2026
400 mg	25 Oct, 2018	1		23 Nov, 2026

Strength	Dosage	Availability
EQ 100MG BASE	TABLET;ORAL	Prescription
EQ 400MG BASE	TABLET;ORAL	Prescription
EQ 500MG BASE	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
90 mg	20 Jul, 2015	16	04 Sep, 2018	17 Apr, 2030	Eligible
60 mg	30 Sep, 2015	3	04 Sep, 2018	17 Apr, 2030	Eligible

Strength	Dosage	Availability
2MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued
2MG	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription
EQ 60MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
2%;70% (3ML)	SPONGE;TOPICAL	Over the counter
2%;70% (10.5ML)	SPONGE;TOPICAL	Over the counter
2%;70% (26ML)	SPONGE;TOPICAL	Over the counter
2%;70% (1ML)	SPONGE;TOPICAL	Over the counter
2%;70% (1.5ML)	SPONGE;TOPICAL	Over the counter

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
500 mcg	02 Mar, 2015	7	13 Jul, 2018	08 Mar, 2024	Eligible
250 mcg	25 Jan, 2019	1	07 Sep, 2022	08 Mar, 2024	Eligible

Strength	Dosage	Availability
30MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription
60MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
24MG;26MG	TABLET;ORAL	Prescription
49MG;51MG	TABLET;ORAL	Prescription
97MG;103MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
EQ 0.75MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 1MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 4MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
200 mg and 300 mg	21 Aug, 2007	1		19 May, 2024	Extinguished
100 mg	23 May, 2014	1		19 May, 2024	Extinguished

Strength	Dosage	Availability
100MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
200MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
300MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
2.5MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
5MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
10MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
15MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription
20MG	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription

Strength	Dosage	Availability
EQ 0.1MG BASE	TABLET;BUCCAL, SUBLINGUAL	Prescription
EQ 0.2MG BASE	TABLET;BUCCAL, SUBLINGUAL	Prescription
EQ 0.3MG BASE	TABLET;BUCCAL, SUBLINGUAL	Discontinued
EQ 0.4MG BASE	TABLET;BUCCAL, SUBLINGUAL	Prescription
EQ 0.6MG BASE	TABLET;BUCCAL, SUBLINGUAL	Prescription
EQ 0.8MG BASE	TABLET;BUCCAL, SUBLINGUAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
500 mg, 750 mg and 1000 mg	27 Oct, 2008	3	11 Aug, 2017	26 Aug, 2024	Deferred
750 mg and 1000 mg	25 Nov, 2015	1		01 Dec, 2030	Extinguished

Strength	Dosage	Availability
EQ 1GM BASE	TABLET, CHEWABLE;ORAL	Prescription
EQ 250MG BASE	TABLET, CHEWABLE;ORAL	Discontinued
EQ 500MG BASE	TABLET, CHEWABLE;ORAL	Prescription
EQ 750MG BASE	TABLET, CHEWABLE;ORAL	Prescription

Strength	Dosage	Availability
EQ 0.25MG BASE	CAPSULE;ORAL	Prescription
EQ 1MG BASE	CAPSULE;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	Last patent expiry
100 mg/2 mL	23 Sep, 2022	1	15 Feb, 2028
750 mg/15 mL	27 Mar, 2019	1	15 Feb, 2028
1 g/20 mL	15 Feb, 2022	1	15 Feb, 2028

Strength	Dosage	Availability
1GM IRON/20ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription
750MG IRON/15ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription
100MG IRON/2ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription
500MG IRON/10ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription

Pharsight

Drug Patents Expiring in 2024

1. List of Abilify drug patents

2. List of Abilify Maintena Kit drug patents

3. List of Abilify Mycite Kit drug patents

4. List of Abraxane drug patents

5. List of Acular Ls drug patents

6. List of Acuvail drug patents

7. List of Adasuve drug patents

8. List of Airduo Digihaler drug patents

9. List of Aldara drug patents

10. List of Aliqopa drug patents

11. List of Aloxi drug patents

12. List of Alphagan P drug patents

13. List of Altabax drug patents

14. List of Amitiza drug patents

15. List of Anjeso drug patents

16. List of Arikayce Kit drug patents

17. List of Armonair Digihaler drug patents

18. List of Atripla drug patents

19. List of Auryxia drug patents

20. List of Auvi-q drug patents

21. List of Bosulif drug patents

22. List of Brilinta drug patents

23. List of Bydureon drug patents

24. List of Bydureon Bcise drug patents

25. List of Cabometyx drug patents

26. List of Children's Advil drug patents

27. List of Children's Advil Allergy Sinus drug patents

28. List of Chloraprep One-step drug patents

29. List of Chlorhexidine Gluconate drug patents

30. List of Combivent Respimat drug patents

31. List of Complera drug patents

32. List of Contrave drug patents

33. List of Daliresp drug patents

34. List of Dexilant drug patents

35. List of Dexilant Solutab drug patents

36. List of Dextenza drug patents

37. List of Differin drug patents

38. List of Dificid drug patents

39. List of Diprivan drug patents

40. List of Duavee drug patents

41. List of Durysta drug patents

42. List of Dutrebis drug patents

43. List of Dymista drug patents

44. List of Entresto drug patents

45. List of Envarsus Xr drug patents

46. List of Epiduo drug patents

47. List of Equetro drug patents

48. List of Evekeo Odt drug patents

49. List of Evoclin drug patents

50. List of Evzio drug patents

51. List of Evzio (autoinjector) drug patents

52. List of Exservan drug patents

53. List of Farxiga drug patents

54. List of Fenoglide drug patents

55. List of Fentora drug patents

56. List of Finacea drug patents

57. List of Flonase Sensimist Allergy Relief drug patents

58. List of Fosrenol drug patents

59. List of Givlaari drug patents

60. List of Gralise drug patents

61. List of Halaven drug patents

62. List of Hycamtin drug patents

63. List of Ilevro drug patents

64. List of Inbrija drug patents

65. List of Injectafer drug patents

66. List of Invokamet drug patents

67. List of Invokamet Xr drug patents

68. List of Ionsys drug patents

69. List of Isentress drug patents

70. List of Ixempra Kit drug patents

71. List of Koselugo drug patents

72. List of Kuvan drug patents

73. List of Kynmobi drug patents

74. List of Latisse drug patents

75. List of Latuda drug patents

76. List of Lazanda drug patents

77. List of Leqvio drug patents

78. List of Linzess drug patents

Strength	Dosage	Availability
50MG;500MG	TABLET;ORAL	Prescription
50MG;1GM	TABLET;ORAL	Prescription
150MG;500MG	TABLET;ORAL	Prescription
150MG;1GM	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
400 mg	12 Oct, 2011	1		11 Mar, 2029
600 mg	21 Oct, 2022	1		30 Mar, 2032

Strength	Dosage	Availability
15MG/VIAL	INJECTABLE;INTRAVENOUS	Prescription
45MG/VIAL	INJECTABLE;INTRAVENOUS	Prescription

Strength	Dosage	Availability
EQ 10MG BASE	CAPSULE;ORAL	Prescription
EQ 25MG BASE	CAPSULE;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg	05 Jun, 2014	1	10 May, 2019	16 Nov, 2025	Eligible
100 mg per packet	09 Nov, 2015	1	20 Aug, 2019	17 May, 2025	Eligible Deferred
500 mg per packet	23 Feb, 2017	1	20 Aug, 2019	01 Nov, 2032	Eligible

Strength	Dosage	Availability
10MG	FILM;SUBLINGUAL	Prescription
15MG	FILM;SUBLINGUAL	Prescription
20MG	FILM;SUBLINGUAL	Prescription
25MG	FILM;SUBLINGUAL	Prescription
30MG	FILM;SUBLINGUAL	Prescription

Strength	Dosage	Availability
EQ 0.1MG BASE	SPRAY, METERED;NASAL	Prescription
EQ 0.3MG BASE	SPRAY, METERED;NASAL	Discontinued
EQ 0.4MG BASE	SPRAY, METERED;NASAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
145 mcg and 290 mcg	30 Aug, 2016	4	09 Feb, 2021	30 Oct, 2031	Deferred
72 mcg	07 Nov, 2017	1		16 Aug, 2033

Strength	Dosage	Availability
72MCG	CAPSULE;ORAL	Prescription
145MCG	CAPSULE;ORAL	Prescription
290MCG	CAPSULE;ORAL	Prescription

Strength	Dosage	Availability
5MG/5ML	SOLUTION;ORAL	Prescription
10MG/5ML	SOLUTION;ORAL	Prescription